enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Buy” from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $33.67.

Several research firms have recently weighed in on ENGN. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th.

enGene Trading Up 2.1 %

enGene stock opened at $8.58 on Thursday. The business has a 50 day moving average price of $6.61 and a two-hundred day moving average price of $9.84. The company has a quick ratio of 19.52, a current ratio of 19.52 and a debt-to-equity ratio of 0.09. The stock has a market cap of $378.94 million, a price-to-earnings ratio of -4.99 and a beta of -0.69. enGene has a 12 month low of $4.42 and a 12 month high of $43.00.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.05. As a group, equities analysts forecast that enGene will post -1.56 EPS for the current year.

Insider Buying and Selling

In other enGene news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $57,000. The purchase was disclosed in a filing with the SEC, which is available through this link. 13.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On enGene

A number of large investors have recently bought and sold shares of ENGN. Janus Henderson Group PLC bought a new stake in enGene during the 1st quarter worth approximately $17,095,000. SR One Capital Management LP bought a new position in enGene in the 2nd quarter valued at $4,715,000. Logos Global Management LP boosted its position in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. bought a new position in enGene in the 1st quarter valued at $2,039,000. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.